Market Overview 2025-2033
The India biosimilar market size is projected to exhibit a growth rate (CAGR) of 18.10% during 2025-2033. The market is expanding rapidly, driven by rising healthcare needs, patent expirations, and cost-effective treatment options. Key trends include increasing regulatory approvals, growing adoption in oncology and autoimmune diseases, and investments in advanced biomanufacturing.
Key Market Highlights:
✔️ Strong market expansion driven by rising healthcare demand & affordability
✔️ Growing adoption of biosimilars in oncology & autoimmune disorders
✔️ Increasing regulatory approvals supporting market growth
✔️ Advancements in biomanufacturing enhancing production efficiency
✔️ Expanding research collaborations to drive innovation & accessibility
Request for a sample copy of this report: https://www.imarcgroup.com/india-biosimilar-market/requestsample
India Biosimilar Market Trends and Drivers:
The India biosimilar market is experiencing significant growth, driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders that require long-term biologic treatments. With the high costs of original biologics, biosimilars present a more affordable alternative, making advanced therapies accessible to a broader patient base.
Government initiatives aimed at expanding healthcare access, along with the rising adoption of biosimilars in public healthcare programs, are further propelling market expansion. Additionally, the expiration of patents for several blockbuster biologic drugs has created opportunities for Indian pharmaceutical companies to develop and launch biosimilars in both domestic and international markets.
Key trends shaping the India biosimilar market include advancements in biotechnological R&D, leading to the production of high-quality, cost-effective biosimilars. Indian pharmaceutical firms are increasingly investing in research and forming strategic alliances with global players to strengthen their biosimilar portfolios and expand market presence. Another notable trend is the growing acceptance of biosimilars among healthcare professionals and patients, fueled by greater awareness and confidence in their safety and efficacy.
Furthermore, Indian regulatory authorities are streamlining approval processes to facilitate the development and commercialization of biosimilars, further accelerating market growth. As the demand for affordable biologic therapies continues to rise, India is poised to emerge as a key player in the global biosimilar market in the years ahead.
India Biosimilar Market Segmentation:
The report segments the market based on product type, distribution channel, and region:
Study Period:
Base Year: 2024
Historical Year: 2019-2024
Forecast Year: 2025-2033
Breakup by Molecule:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
- Pegfilgrastim
- Trastuzumab
- Bevacizumab
- Others
Breakup by Indication Insights:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
- Others
Breakup by Manufacturing Type:
- In-house Manufacturing
- Contract Manufacturing
Breakup by Region:
- North India
- West and Central India
- South India
- East and Northeast India
Competitive Landscape:
The market research report offers an in-depth analysis of the competitive landscape, covering market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant. Additionally, detailed profiles of all major companies are included.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Market Outlook 